These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 1535170)
1. Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity. Yap I; Guan R; Chan SH Vaccine; 1992; 10(7):439-42. PubMed ID: 1535170 [TBL] [Abstract][Full Text] [Related]
2. Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines. Yap I; Guan R; Chan SH J Gastroenterol Hepatol; 1995; 10(1):51-5. PubMed ID: 7620108 [TBL] [Abstract][Full Text] [Related]
3. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study. Goh KT; Tan KL; Kong KH; Oon CJ; Chan SH Bull World Health Organ; 1992; 70(2):233-9. PubMed ID: 1600584 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults. Raz R; Koren R; Bass D Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients. Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664 [TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates. Yerushalmi B; Raz R; Blondheim O; Shumov E; Koren R; Dagan R Pediatr Infect Dis J; 1997 Jun; 16(6):587-92. PubMed ID: 9194109 [TBL] [Abstract][Full Text] [Related]
7. Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. Hourvitz A; Mosseri R; Solomon A; Yehezkelli Y; Atsmon J; Danon YL; Koren R; Shouval D J Viral Hepat; 1996 Jan; 3(1):37-42. PubMed ID: 8736239 [TBL] [Abstract][Full Text] [Related]
8. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates. Gunn TR; Bosley A; Woodfield DG N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a low dose recombinant DNA hepatitis B vaccine in healthy adults in Singapore. Guan R; Tay HH; Yap I; Smith R; Tan LH Asian Pac J Allergy Immunol; 1989 Dec; 7(2):85-8. PubMed ID: 2533866 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens. Soulié JC; Devillier P; Santarelli J; Goudeau A; Vermeulen P; Guellier M; Saliou P; Hillion AM; Tron F; Huchet J Vaccine; 1991 Aug; 9(8):545-8. PubMed ID: 1837646 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a 'pre-S2 plus S' hepatitis B vaccine in healthy adults. Katkov WN; Watkins E; DeMelia HC; Dienstag JL J Viral Hepat; 1994; 1(1):79-83. PubMed ID: 8790563 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of low doses of recombinant hepatitis B vaccine in young males. Tsakalakis C; Richardson SC; Roumeliotou-Karayannis A; Papaevangelou G Vaccine; 1988 Aug; 6(4):328-30. PubMed ID: 2973188 [TBL] [Abstract][Full Text] [Related]
13. [Immunogenicity and harmlessness in the newborn of a vaccine (GenHevac B) containing the antigens S and pre-S2]. Tron F; Soulié JC; Goudeau A; Devillier P; Saliou P Bull Soc Pathol Exot; 1991; 84(5 Pt 5):901-5. PubMed ID: 1840243 [TBL] [Abstract][Full Text] [Related]
14. Comparative safety and immunogenicity of yeast recombinant hepatitis B vaccines containing S and pre-S2 + S antigens. Miskovsky E; Gershman K; Clements ML; Cupps T; Calandra G; Hesley T; Ioli V; Ellis R; Kniskern P; Miller W Vaccine; 1991 May; 9(5):346-50. PubMed ID: 1872019 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in young adults. Bruguera M; Bayas JM; Vilella A; Tural C; González A; Vidal J; Dal-Ré R; Salleras L Vaccine; 1996 Oct; 14(15):1407-11. PubMed ID: 8994314 [TBL] [Abstract][Full Text] [Related]
16. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Shouval D; Ilan Y; Adler R; Deepen R; Panet A; Even-Chen Z; Gorecki M; Gerlich WH Vaccine; 1994 Nov; 12(15):1453-9. PubMed ID: 7533967 [TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of low dose intradermally administered hepatitis B vaccine: a comparison of plasma-derived and recombinant yeast-derived vaccines. Söyletir G; Bahçeci E; Akoğlu E; Soyoğul U; Lawrance RA Vaccine; 1992; 10(5):301-4. PubMed ID: 1533478 [TBL] [Abstract][Full Text] [Related]
18. Comparative trial of low-dose, intradermal, recombinant- and plasma-derived hepatitis B vaccines. Bryan JP; Sjogren M; Iqbal M; Khattak AR; Nabi S; Ahmed A; Cox B; Morton A; Shuck J; Macarthy P J Infect Dis; 1990 Oct; 162(4):789-93. PubMed ID: 2144866 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and protective efficacy of low dose recombinant DNA hepatitis B vaccine in normal and high-risk neonates. Assateerawatt A; Tanphaichitr VS; Suvatte V; In-ngarm L Asian Pac J Allergy Immunol; 1991 Dec; 9(2):89-93. PubMed ID: 1839654 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the immunogenicity of hepatitis B vaccine administered intradermally and intramuscularly. King JW; Taylor EM; Crow SD; White MC; Todd JR; Poe MB; Conrad SA; Gelder FB Rev Infect Dis; 1990; 12(6):1035-43. PubMed ID: 2148433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]